James Albiero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Albiero has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Josmar Mazucheli
Programa de Pós-Graduação em Bioestatística, Departamento de Estatística, Universidade Estadual de Maringá, Maringá, Brazil
5 shared publications- Maria Cristina Bronharo Tognim
Laboratório de Microbiologia, Departamento de Ciências Básicas da Saúde, Universidade Estadual de Maringá, Maringá, Brazil
5 shared publications - Sherwin Kenneth B. Sy
School of Medicine and Pharmacy Ocean University of China Qingdao China
4 shared publications Floristher Elaine Carrara-Marroni
Departamento de Patologia, Análises Clínicas e Toxicológicas, Universidade Estadual de Londrina, Maringá, Brazil
3 shared publicationsF.V. Fabri
Univ Estadual Maringa, Maringa, Parana, Brazil
2 shared publicationsFernanda Gomes Lodi
Laboratório de Microbiologia Médica, Departamento de Ciências Básicas da Saúde, Universidade Estadual de Maringá, Maringá, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 July 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (7) , 1886-1895
FARMACOS ANTIDEPRESSIVOS USADOS NO TRATAMENTO DA DEPRESSÃO EM ESTUDANTES DE MEDICINA E SEU IMPACTO EM SUA VIDA ACADÊMICA.
OBJETIVO: Caracterizar um perfil relacionado ao uso de fármacos no transtorno depressivo em acadêmicos de medicina e como interfere na vida acadêmica. MÉTODO: Trata-se de um estudo quantitativo descritivo cujos dados foram obtidos através de pesquisa de campo por meio do Formulário do Google, autorizado e realizado dentro do Centro Universitário Fundação Assis Gurgacz. Os acadêmicos enquadrados na pesquisa são aqueles que apresentam ou apresentaram diagnóstico de Depressão em algum momento da vida, e qual a interferencia no dia a dia. RESULTADO: Os acadêmicos relataram que, a depressão apresenta gatilhos que os impedem de melhor proveito da vida acadêmica, como o desânimo ou cansaço repentino. Além de que, a maioria dos pesquisados, moram sozinhos e apresentam diagnósticos diferenciais associados a depressão.
- 1 July 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (7) , 1886-1895
Open AccessFARMACOS ANTIDEPRESSIVOS USADOS NO TRATAMENTO DA DEPRESSÃO EM ESTUDANTES DE MEDICINA E SEU IMPACTO EM SUA VIDA ACADÊMICA.
OBJETIVO: Caracterizar um perfil relacionado ao uso de fármacos no transtorno depressivo em acadêmicos de medicina e como interfere na vida acadêmica. MÉTODO: Trata-se de um estudo quantitativo descritivo cujos dados foram obtidos através de pesquisa de campo por meio do Formulário do Google, autorizado e realizado dentro do Centro Universitário Fundação Assis Gurgacz. Os acadêmicos enquadrados na pesquisa são aqueles que apresentam ou apresentaram diagnóstico de Depressão em algum momento da vida, e qual a interferencia no dia a dia. RESULTADO: Os acadêmicos relataram que, a depressão apresenta gatilhos que os impedem de melhor proveito da vida acadêmica, como o desânimo ou cansaço repentino. Além de que, a maioria dos pesquisados, moram sozinhos e apresentam diagnósticos diferenciais associados a depressão.
- Open Access
- 13 September 2023
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 22 (2) , 283-291
Reconciliação medicamentosa na admissão e orientação farmacêutica na alta em um hospital de pequeno porte no Paraná
Introdução: a reconciliação medicamentosa e orientação na alta são essenciais para identificar e minimizar fatores de risco relacionados a medicamento, entretanto em hospitais de pequeno porte a farmácia clínica ainda é pouco explorada. Objetivo: Realizar um estudo prospectivo de reconciliação medicamentosa e orientação farmacêutica na alta em um hospital de pequeno porte. Metodologia: foi realizado um estudo piloto, prospectivo, descritivo e de caráter exploratório envolvendo trinta pacientes admitidos no hospital, acompanhados desde a admissão, realizando reconciliação medicamentosa, até alta hospitalar, recebendo orientação farmacêutica. Resultados: houve predominância do sexo feminino (57%), média de idade de 71 anos e tempo de internação de 3 dias. A maior causa de internação foi pielonefrite (23%) e a comorbidade mais frequente foi hipertensão (60%). Os medicamentos mais utilizados previamente foram do sistema nervoso e cardiovascular (37%). Após reconciliação foram encontradas 100 discrepâncias, 10% de forma intencional, com maior frequência de substituição de medicamentos (70%), e 90% não intencional, onde a maioria foi omissão de medicamentos (98%). Noventa e cinco por cento dos medicamentos de uso prévio estavam envolvidos nas discrepâncias. A classe mais envolvida foi do sistema cardiovascular (42%). Em 50% dos prontuários não havia menção pelo médico das comorbidades do paciente, e em 24% a enfermagem também não mencionou. Apenas 43% dos medicamentos prescritos na alta faziam parte da Relação Municipal de Medicamentos. Conclusão: houve alta frequência de discrepâncias de medicamentos, principalmente de forma não intencional, destacando omissão de medicamentos. A reconciliação medicamentosa e orientação na alta podem contribuir para a segurança do paciente na transição de cuidados.
- 13 September 2023
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 22 (2) , 283-291
Open AccessReconciliação medicamentosa na admissão e orientação farmacêutica na alta em um hospital de pequeno porte no Paraná
Introdução: a reconciliação medicamentosa e orientação na alta são essenciais para identificar e minimizar fatores de risco relacionados a medicamento, entretanto em hospitais de pequeno porte a farmácia clínica ainda é pouco explorada. Objetivo: Realizar um estudo prospectivo de reconciliação medicamentosa e orientação farmacêutica na alta em um hospital de pequeno porte. Metodologia: foi realizado um estudo piloto, prospectivo, descritivo e de caráter exploratório envolvendo trinta pacientes admitidos no hospital, acompanhados desde a admissão, realizando reconciliação medicamentosa, até alta hospitalar, recebendo orientação farmacêutica. Resultados: houve predominância do sexo feminino (57%), média de idade de 71 anos e tempo de internação de 3 dias. A maior causa de internação foi pielonefrite (23%) e a comorbidade mais frequente foi hipertensão (60%). Os medicamentos mais utilizados previamente foram do sistema nervoso e cardiovascular (37%). Após reconciliação foram encontradas 100 discrepâncias, 10% de forma intencional, com maior frequência de substituição de medicamentos (70%), e 90% não intencional, onde a maioria foi omissão de medicamentos (98%). Noventa e cinco por cento dos medicamentos de uso prévio estavam envolvidos nas discrepâncias. A classe mais envolvida foi do sistema cardiovascular (42%). Em 50% dos prontuários não havia menção pelo médico das comorbidades do paciente, e em 24% a enfermagem também não mencionou. Apenas 43% dos medicamentos prescritos na alta faziam parte da Relação Municipal de Medicamentos. Conclusão: houve alta frequência de discrepâncias de medicamentos, principalmente de forma não intencional, destacando omissão de medicamentos. A reconciliação medicamentosa e orientação na alta podem contribuir para a segurança do paciente na transição de cuidados.
- 31 October 2019
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 25 (9) , 1266-1274
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information
Aim: The aims of the study are to evaluate the activity of sulbactam, meropenem, and polymyxin B alone and in combination against six isolates of extremely drug resistant Acinetobacter baumannii and to determine dosing regimens that achieve a sufficient joint probability of target attainment (PTA) based on combination antimicrobial pharmacodynamics. Materials and Methods: The combinations were evaluated by the checkerboard method and were considered synergistic when the fractional inhibitory concentration index (FICI) ≤0.5. Pharmacodynamic analyses were carried out by evaluating dosing regimens that achieve ≥90% joint PTA at the percentage of time over a 24-h period wherein the free drug concentration is above the minimum inhibitory concentration (% f T> MIC) of 40% and 60% for meropenem and sulbactam, respectively, and 20 for the ratio of the area under the free drug concentration-time curve over MIC ( f AUC/MIC) for polymyxin B. Results: For both polymyxin B-resistant and susceptible isolates, the addition of sulbactam in combination with meropenem and subinhibitory concentration of polymyxin B showed important synergistic activity (five isolates; FICI ≤0.281); the recommended dosing regimens were 2/4 g meropenem/sulbactam q8 hours and 0.5 mg/kg polymyxin B q12 hours. Conclusion: This in vitro study showed that sulbactam can significantly improve the action of meropenem and polymyxin B in OXA-producing A. baumannii isolates, especially when there are no new treatment options available for infections caused by these microorganisms.
- 31 October 2019
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 25 (9) , 1266-1274
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information
Aim: The aims of the study are to evaluate the activity of sulbactam, meropenem, and polymyxin B alone and in combination against six isolates of extremely drug resistant Acinetobacter baumannii and to determine dosing regimens that achieve a sufficient joint probability of target attainment (PTA) based on combination antimicrobial pharmacodynamics. Materials and Methods: The combinations were evaluated by the checkerboard method and were considered synergistic when the fractional inhibitory concentration index (FICI) ≤0.5. Pharmacodynamic analyses were carried out by evaluating dosing regimens that achieve ≥90% joint PTA at the percentage of time over a 24-h period wherein the free drug concentration is above the minimum inhibitory concentration (% f T> MIC) of 40% and 60% for meropenem and sulbactam, respectively, and 20 for the ratio of the area under the free drug concentration-time curve over MIC ( f AUC/MIC) for polymyxin B. Results: For both polymyxin B-resistant and susceptible isolates, the addition of sulbactam in combination with meropenem and subinhibitory concentration of polymyxin B showed important synergistic activity (five isolates; FICI ≤0.281); the recommended dosing regimens were 2/4 g meropenem/sulbactam q8 hours and 0.5 mg/kg polymyxin B q12 hours. Conclusion: This in vitro study showed that sulbactam can significantly improve the action of meropenem and polymyxin B in OXA-producing A. baumannii isolates, especially when there are no new treatment options available for infections caused by these microorganisms.
- 1 June 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (6)
Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase
Fosfomycin combined with other antimicrobials has shown good efficacy against multidrug-resistant (MDR) bacteria in both in vitro and clinical studies; however, the activity of fosfomycin combined with other antimicrobials against metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa strains has not been tested. The objective of this study was to determine the synergism and optimal intravenous dosing regimens of fosfomycin with meropenem against MDR and MBL-producing P. aeruginosa strains.
- 1 June 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (6)
Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase
Fosfomycin combined with other antimicrobials has shown good efficacy against multidrug-resistant (MDR) bacteria in both in vitro and clinical studies; however, the activity of fosfomycin combined with other antimicrobials against metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa strains has not been tested. The objective of this study was to determine the synergism and optimal intravenous dosing regimens of fosfomycin with meropenem against MDR and MBL-producing P. aeruginosa strains.
- Open Access
- 1 August 2018
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 73, 56
Pharmacodynamic evaluation of vancomycin by Monte Carlo simulation against Staphylococcus spp isolated in a hospital teaching
- 1 August 2018
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 73, 56
Open AccessPharmacodynamic evaluation of vancomycin by Monte Carlo simulation against Staphylococcus spp isolated in a hospital teaching
- Open Access
- 1 August 2018
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 73, 144-145
Can susceptibility methods affect the vancomycin therapeutic target?
- 1 August 2018
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 73, 144-145
Open AccessCan susceptibility methods affect the vancomycin therapeutic target?
- 1 August 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (8)
Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities
Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gram-negative bacterial isolates, consisting of 158 Escherichia coli isolates and 87 Klebsiella isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against E. coli (MIC 90 ≤ 16 μg/ml) but not against Klebsiella spp. (MIC 90 > 512 μg/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an E. coli isolate with an MIC of ≤64 mg/liter was able to achieve a PTA of ≥90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against E. coli and Klebsiella spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both E. coli and Klebsiella isolates.
- 1 August 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (8)
Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities
Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gram-negative bacterial isolates, consisting of 158 Escherichia coli isolates and 87 Klebsiella isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against E. coli (MIC 90 ≤ 16 μg/ml) but not against Klebsiella spp. (MIC 90 > 512 μg/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an E. coli isolate with an MIC of ≤64 mg/liter was able to achieve a PTA of ≥90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against E. coli and Klebsiella spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both E. coli and Klebsiella isolates.
- 1 November 2016
- Published by Elsevier in American Journal of Infection Control
- Vol. 44 (11) , 1374-1380
Outbreak of Klebsiella pneumoniae carbapenemase–producing K pneumoniae: A systematic review
- 1 November 2016
- Published by Elsevier in American Journal of Infection Control
- Vol. 44 (11) , 1374-1380
Outbreak of Klebsiella pneumoniae carbapenemase–producing K pneumoniae: A systematic review
- Open Access
- 1 July 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (7) , 4128-4139
Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
KPC-producingKlebsiella pneumoniaecauses serious infections associated with high death rates worldwide. Combination therapy consisting of fosfomycin and a carbapenem is better than monotherapy to combat multidrug-resistant microorganisms, but no dosages for the combination have been defined. The MICs of meropenem and fosfomycin were evaluated against 18 clinical isolates of KPC-2-producingK. pneumoniae. The activities of combination antimicrobials were also determined by the checkerboard method. The MIC50and MIC90of each agent alone and in combination were challenged against short (1.5-h) or prolonged (3-h) infusion regimens of meropenem (1 g every 8 h [q8h], 1.5 g q6h, 2 g q8h) and fosfomycin (4 g q8h, 6 g q6h, 8 g q8h) by Monte Carlo simulation to evaluate the time above the MIC of the free drug concentration as a percentage of the dosing interval (fT>MIC). The monotherapy MIC50s and MIC90s were 32 and 256 mg/liter for meropenem and 64 and 512 mg/liter for fosfomycin, respectively. Antimicrobial combination increased bacterial susceptibility to 1/4 the MIC50s and to 1/8 to 1/16 the MIC90s of monotherapy. The antimicrobial combination demonstrated a synergistic effect for at least two-thirds of the isolates. In combination therapy, fosfomycin regimens of 6 g q6h and 8 g q8h as a 3-h infusion against the MIC50and MIC90had better chances of achieving ≥90% probability of target attainment (PTA) of 70%fT>MIC. Meropenem regimens of 1.5 g q6h and 2 g q8h in prolonged infusion can achieve close to 90% PTA of 40%fT>MIC for MIC50but not MIC90. The significant reduction in the MIC values and the achievement of appropriate PTA demonstrated that regimens containing fosfomycin with meropenem can be effective against KPC-2-producingK. pneumoniae.
- 1 July 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (7) , 4128-4139
Open AccessPharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
KPC-producingKlebsiella pneumoniaecauses serious infections associated with high death rates worldwide. Combination therapy consisting of fosfomycin and a carbapenem is better than monotherapy to combat multidrug-resistant microorganisms, but no dosages for the combination have been defined. The MICs of meropenem and fosfomycin were evaluated against 18 clinical isolates of KPC-2-producingK. pneumoniae. The activities of combination antimicrobials were also determined by the checkerboard method. The MIC50and MIC90of each agent alone and in combination were challenged against short (1.5-h) or prolonged (3-h) infusion regimens of meropenem (1 g every 8 h [q8h], 1.5 g q6h, 2 g q8h) and fosfomycin (4 g q8h, 6 g q6h, 8 g q8h) by Monte Carlo simulation to evaluate the time above the MIC of the free drug concentration as a percentage of the dosing interval (fT>MIC). The monotherapy MIC50s and MIC90s were 32 and 256 mg/liter for meropenem and 64 and 512 mg/liter for fosfomycin, respectively. Antimicrobial combination increased bacterial susceptibility to 1/4 the MIC50s and to 1/8 to 1/16 the MIC90s of monotherapy. The antimicrobial combination demonstrated a synergistic effect for at least two-thirds of the isolates. In combination therapy, fosfomycin regimens of 6 g q6h and 8 g q8h as a 3-h infusion against the MIC50and MIC90had better chances of achieving ≥90% probability of target attainment (PTA) of 70%fT>MIC. Meropenem regimens of 1.5 g q6h and 2 g q8h in prolonged infusion can achieve close to 90% PTA of 40%fT>MIC for MIC50but not MIC90. The significant reduction in the MIC values and the achievement of appropriate PTA demonstrated that regimens containing fosfomycin with meropenem can be effective against KPC-2-producingK. pneumoniae.
- 1 May 2016
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 47 (5) , 380-385
Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections
- 1 May 2016
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 47 (5) , 380-385
Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections